Valuation: Vaxart, Inc.

Market Cap 9.92Cr 8.9Cr 8.23Cr 7.45Cr 14Cr 945.03Cr 14Cr 98Cr 39Cr 494.51Cr 37Cr 36Cr 1.57TCr P/E 2026 *
-2.55x
P/E 2027 * -0.48x
Enterprise Value 9.92Cr 8.9Cr 8.23Cr 7.45Cr 14Cr 945.03Cr 14Cr 98Cr 39Cr 494.51Cr 37Cr 36Cr 1.57TCr EV / Sales 2026 *
0.84x
EV / Sales 2027 * 42.2x
Free-Float
98.49%
Yield 2026 *
-
Yield 2027 * -
1 day+2.73%
1 week-4.97%
Current month-6.87%
1 month-6.91%
3 months-13.18%
6 months-44.58%
Current year+20.99%
1 week 0.35
Extreme 0.3501
0.45
1 month 0.35
Extreme 0.3501
0.52
Current year 0.34
Extreme 0.3434
0.84
1 year 0.3
Extreme 0.305
0.84
3 years 0.26
Extreme 0.2606
1.54
5 years 0.26
Extreme 0.2606
8.13
10 years 0.25
Extreme 0.2543
24.9
Manager TitleAgeSince
Chief Executive Officer 60 18/03/2024
Chief Tech/Sci/R&D Officer 59 01/03/2024
Director of Finance/CFO - 19/05/2025
Director TitleAgeSince
Director/Board Member 68 21/04/2021
Director/Board Member 76 04/08/2022
Director/Board Member 79 01/01/2022
Date Insider Type Main position Quantity % Market Cap. Importance
16/07/26 Free

Director

1,18,100 0.0488%
16/07/26 Free

Director

1,18,100 0.0488%
16/07/26 Free

Director

1,18,100 0.0488%
Change 5-day change 1-year change 3-year change Capi.($)
+2.73%-4.97%+19.10%-36.50% 9.92Cr
+0.34%-3.03%+37.45%+61.06% 6.41TCr
+0.83%+2.53%+12.08%+83.63% 5.55TCr
+1.06%+1.53%+12.77%+104.75% 5.3TCr
-1.11%-0.98%+26.52%+55.56% 4.6TCr
+0.01%-2.11%+18.85%+100.52% 4.25TCr
+0.34%+1.61%+228.68%+939.25% 4.04TCr
+0.64%-3.95%+11.15%+45.57% 3.23TCr
-1.71%+43.03%+104.20%+90.66% 3.45TCr
-2.72%-0.44%+23.18%-10.77% 2.42TCr
Average +0.02%+2.06%+49.40%+143.37% 3.93TCr
Weighted average by Cap. -0.07%+3.15%+49.75%+161.11%

Financials

2026 *2027 *
Net sales 12Cr 11Cr 9.84Cr 8.91Cr 17Cr 1.13TCr 17Cr 117.62Cr 47Cr 591.07Cr 45Cr 44Cr 1.88TCr 23.5L 21.08L 19.49L 17.65L 32.98L 22Cr 33.38L 2.33Cr 92.83L 12Cr 88.19L 86.32L 37Cr
Net income -4.72Cr -4.23Cr -3.92Cr -3.55Cr -6.62Cr -449.54Cr -6.7Cr -47Cr -19Cr -235.23Cr -18Cr -17Cr -746.78Cr -22Cr -20Cr -18Cr -17Cr -31Cr -2.11TCr -31Cr -219.76Cr -88Cr -1.1TCr -83Cr -81Cr -3.51TCr
Net Debt - -
Projected Income Statement - Annual - Vaxart, Inc.
Logo Vaxart, Inc.
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The Company’s development programs include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), its first immune-oncology indication. The Company's platform technology employs a vector-based approach and consists of various components, such as vector, antigen, and adjuvant. A vector is a virus used as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. An antigen is a viral or bacterial protein that stimulates an immune response to the targeted pathogen.
Employees
65
Date Price Change Volume
29/26/29 $0.4191 +2.73% 65,268
28/26/28 $0.4080 +2.26% 5,76,971
27/26/27 $0.3990 -1.48% 2,07,933
26/26/26 $0.4050 -1.22% 3,52,786
23/26/23 $0.4100 -7.03% 3,39,460
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Vaxart, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.4080USD
Average target price
3.333USD
Spread / Average Target
+716.99%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Vaxart, Inc.
  1. Stock Market
  2. Stocks
  3. VXRT Stock